{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:15Z","timestamp":1776413115027,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013405","name":"Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.medcli.2025.107179","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:16:53Z","timestamp":1758939413000},"page":"107179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes"],"prefix":"10.1016","volume":"165","author":[{"given":"Jorge Gabriel","family":"Ruiz-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Miguel","family":"Sierra Poyatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdana","family":"Luiza Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"S\u00e1nchez-Lechuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiara","family":"Modro\u00f1o M\u00f3stoles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Montoya \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"S\u00e1nchez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Casado Cases","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"P\u00e9rez de Arenaza Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jersy Jair","family":"C\u00e1rdenas-Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107179_bib0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.medcli.2025.107179_bib0160","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2025.107179_bib0165","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.medcli.2025.107179_bib0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials","volume":"71","author":"Ussher","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.medcli.2025.107179_bib0175","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107179_bib0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107179_bib0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.medcli.2025.107179_bib0190","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107179_bib0195","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s13300-020-00984-x","article-title":"Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study","volume":"12","author":"Jain","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.medcli.2025.107179_bib0200","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clinthera.2021.03.003","article-title":"Real-world effectiveness of once-weekly semaglutide from a US commercially insured and medicare advantage population","volume":"43","author":"Visaria","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.medcli.2025.107179_bib0205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark\/Sweden multicentre, prospective, observational study","volume":"15","author":"Rajamand Ekberg","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.medcli.2025.107179_bib0210","doi-asserted-by":"crossref","first-page":"108931","DOI":"10.1016\/j.diabres.2021.108931","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study","volume":"178","author":"Rudofsky","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.medcli.2025.107179_bib0215","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s13300-021-01141-8","article-title":"Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study","volume":"12","author":"Holmes","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.medcli.2025.107179_bib0220","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13300-021-01010-4","article-title":"Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational EXPERT study","volume":"12","author":"Lingvay","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.medcli.2025.107179_bib0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002619","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups","volume":"10","author":"Yale","year":"2022","journal-title":"BMJ Open Diabetes Res care"},{"key":"10.1016\/j.medcli.2025.107179_bib0230","doi-asserted-by":"crossref","first-page":"108874","DOI":"10.1016\/j.jdiacomp.2024.108874","article-title":"REAL life study of subcutaneous semaglutide in patients with type 2 diabetes in Spain: ambispective, multicenter clinical study. Results in the GLP1-experienced cohort","volume":"38","author":"C\u00e1rdenas-Salas","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.medcli.2025.107179_bib0235","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2022.08.004","article-title":"An endorsement of the removal of race from GFR estimation equations: a position statement from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"80","author":"Kramer","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2025.107179_bib0240","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","article-title":"Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients","volume":"45","author":"Marzullo","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.medcli.2025.107179_bib0245","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s13300-021-01015-z","article-title":"Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study","volume":"12","author":"Williams","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.medcli.2025.107179_bib0250","doi-asserted-by":"crossref","first-page":"851035","DOI":"10.3389\/fendo.2022.851035","article-title":"Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice","volume":"13","author":"P\u00e9rez-Belmonte","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.medcli.2025.107179_bib0255","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1111\/dom.14117","article-title":"Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study)","volume":"22","author":"Brown","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107179_bib0260","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41371-021-00630-4","article-title":"Is it time to reconsider the treatment paradigm for obese patients with hypertension?","volume":"36","author":"Kennedy","year":"2022","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.medcli.2025.107179_bib0265","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030772","article-title":"The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis","volume":"12","author":"Kennedy","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2025.107179_bib0270","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.medcli.2025.107179_bib0275","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin\u2013angiotensin\u2013aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2025.107179_bib0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107179_bib0285","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man","volume":"104","author":"Asmar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2025.107179_bib0290","first-page":"5","article-title":"Liraglutide treatment may affect renin and aldosterone release","volume":"49","author":"Sedman","year":"2017","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.medcli.2025.107179_bib0295","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1152\/ajpendo.00429.2014","article-title":"Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men","volume":"308","author":"Asmar","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.medcli.2025.107179_bib0300","doi-asserted-by":"crossref","first-page":"E744","DOI":"10.1152\/ajpendo.00518.2015","article-title":"Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy","volume":"310","author":"Asmar","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:44:54Z","timestamp":1771508694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325004075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0025775325004075"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107179","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107179"}}